Literature DB >> 18482560

CD28 superagonists: what makes the difference in humans?

Burkhart Schraven1, Ulrich Kalinke.   

Abstract

In 2006, a clinical trial with the CD28 superagonistic antibody TGN1412 in London turned into a catastrophe. Studies are beginning to unravel the difference between the human and preclinical animal response to the antibody.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18482560     DOI： 10.1016/j.immuni.2008.04.003

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  19 in total

1.  Fab-arm exchange.

Authors:  Ellen Broug; Philip A Bland-Ward; John Powell; Kevin S Johnson
Journal:  Nat Biotechnol       Date:  2010-02       Impact factor: 54.908

2.  Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation.

Authors:  Paula C Soto; Lance L Stein; Nancy Hurtado-Ziola; Stephen M Hedrick; Ajit Varki
Journal:  J Immunol       Date:  2010-03-15       Impact factor: 5.422

Review 3.  Delivering safer immunotherapies for cancer.

Authors:  Lauren Milling; Yuan Zhang; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2017-05-22       Impact factor: 15.470

4.  Generation of induced regulatory T cells from primary human naïve and memory T cells.

Authors:  Gavin I Ellis; Mary Catherine Reneer; Alejandra Catalina Vélez-Ortega; Andrea McCool; Francesc Martí
Journal:  J Vis Exp       Date:  2012-04-16       Impact factor: 1.355

Review 5.  The safety and side effects of monoclonal antibodies.

Authors:  Trevor T Hansel; Harald Kropshofer; Thomas Singer; Jane A Mitchell; Andrew J T George
Journal:  Nat Rev Drug Discov       Date:  2010-03-22       Impact factor: 84.694

Review 6.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber's amaurosis.

Authors:  Katherine A High
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

Review 8.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

Review 9.  Human T regulatory cell therapy: take a billion or so and call me in the morning.

Authors:  James L Riley; Carl H June; Bruce R Blazar
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

10.  Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice.

Authors:  Tea Gogishvili; Daniela Langenhorst; Fred Lühder; Fernando Elias; Karin Elflein; Kevin M Dennehy; Ralf Gold; Thomas Hünig
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.